Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXN-2510 Monotherapy in Advanced Solid Tumors
NCT07159828Phase 1Terminated
- Sponsor
- Axion BioSystems
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMM2510 in solid tumor, sponsored by Axion BioSystems. Primary endpoints: Dose-Limiting Toxicities at 3 weeks and Adverse Events and Serious Adverse Events. Started Sep 2025; status: terminated.
02
Drugs
IMM2510
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07159828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159828.